DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Vicriviroc is an investigational drug.
There have been 13 clinical trials for Vicriviroc. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2007.
The most common disease conditions in clinical trials are HIV Infections, Immunologic Deficiency Syndromes, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases (NIAID), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Recent Clinical Trials for Vicriviroc
|Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)||Merck Sharp & Dohme Corp.||Phase 2|
|Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 1|
|Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Phase 1/Phase 2|